MicroRNA-638 inhibits the progression of breast cancer through targeting HOXA9 and suppressing Wnt/β-cadherin pathway

World Journal of Surgical Oncology

Qian Xu¹  Qianqian Zhang¹  Yuan Yu¹  Mengli Dong¹ 

[1] Department of Oncology, Weifang People’s Hospital, No. 151, Guangwen Street, Kuiwen District, 261041, Weifang, People’s Republic of China;

关键词: miR-638;    HOXA9;    Breast cancer;    Wnt/β-cadherin pathway;   

DOI  :  10.1186/s12957-021-02363-7

来源: Springer

【 摘 要 】

BackgroundPrevious studies had shown that microRNA-638 (miR-638) exhibited different effects in malignant tumors. Moreover, the function of miR-638 has not been reported in breast cancer. Hence, we designed this research to explore the function of miR-638 in breast cancer.MethodsFirstly, miR-638 expressions were measured in breast cancer tissues via RT-qPCR. Protein expressions were detected through immunocytochemical (IHC) assay and western blot analysis. Then, Cell Counting Kit-8 (CCK-8) assay and Transwell assay were conducted to observe proliferation and motility of the cells. Dual luciferase assay was performed to confirm the binding site between miR-638 and Homeobox protein Hox-A9 (HOXA9).ResultsReduced expression of miR-638 was detected in breast cancer. And low miR-638 expression was related to poor prognosis in patients with breast cancer. Functionally, the viability, migration, and invasion of the breast cancer cells were suppressed by miR-638 overexpression. Furthermore, miR-638 can directly bind to HOXA9, and increased expression of HOXA9 was also detected in breast cancer. In particular, HOXA9 upregulation can impair anti-tumor effect of miR-638 in breast cancer, and miR-638 can hinder the Wnt/β-cadherin pathway and epithelial-mesenchymal transition (EMT) in breast cancer.ConclusionmiR-638 inhibits breast cancer progression through binding to HOXA9.

【 授权许可】

CC BY